However, they have proved that prediction models based on 18F-FDG PET/CT imaging features can help differentiate EGFR mutation status in NSCLC, which is crucial in clinical practice to identify candidates for targeted therapy (39–44). Here, EGFR is linked to non-small cell lung carcinoma.